[Updated 7/8/19, 9:22 am. See below.] Gene therapy for hemophilia is as close as it’s ever been to market. And the race to get there got more heated this past weekend at a medical meeting in Australia.
At the International Society on Thrombosis and Haemostasis meeting in Melbourne, Sangamo Therapeutics (NASDAQ: SGMO) and partner Pfizer (NYSE: PFE) disclosed the latest results from an early-stage study, Alta, of a gene therapy for hemophilia called SB-525.
The treatment is one of three in human testing for hemophilia A, the most common form of the chronic blood disease. The most… Read more »
UNDERWRITERS AND PARTNERS
